A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

NCT07661173 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Firmonertinib
DRUG: Firmonertinib/pemetrexed/Carboplatin
DRUG: Firmonertinib/pemetrexed/Carboplatin/Bevacizumab

Sponsor

Anhui Provincial Cancer Hospital